Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.
Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.